Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?
Authors: Park JS, Bae SH PMID: 32937686 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - September 18, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Obesity and binge alcohol intake are deadly combination to induce steatohepatitis: A model of high-fat diet and binge ethanol intake.
Authors: Hwang S, Ren T, Gao B Abstract Obesity and binge drinking often coexist and work synergistically to promote steatohepatitis; however, the underlying mechanisms remain obscure. In this mini-review, we briefly summarize clinical evidence of the synergistical effect of obesity and heavy drinking on steatohepatitis and discuss the underlying mechanisms obtained from the study of several mouse models. High-fat diet (HFD) feeding and binge ethanol synergistically induced steatohepatitis and fibrosis in mice with significant intrahepatic neutrophil infiltration; such HFD-plus-ethanol treatment markedly up-regulat...
Source: Clinical and molecular hepatology - September 18, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Acute-on-chronic liver failure as a major predictive factor for mortality in patients with variceal bleeding.
This study examined the risk factors associated with mortality in cirrhotic patients hospitalized with variceal bleeding, and evaluated the effects of acute-on-chronic liver failure (ACLF) on the prognosis of these patients. Methods: This study was retrospectively conducted on patients registered in the Korean acute-on-chronic liver failure study cohort, and on 474 consecutive cirrhotic patients hospitalized with variceal bleeding from January 2013 to December 2013 at 21 university hospitals. ACLF was defined as described by the European Association for the Study of Liver-Chronic Liver Failure Consortium. Results: ...
Source: Clinical and molecular hepatology - September 18, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology.
Authors: Sookoian S, Pirola CJ Abstract Despite more than two decades of extensive research focusing on nonalcoholic fatty liver disease (NAFLD), no approved therapy for steatohepatitis-the severe histological form of the disease-presently exists. More importantly, new drugs and small molecules with diverse molecular targets on the pathways of hepatocyte injury, inflammation, and fibrosis cannot achieve the primary efficacy endpoints. Precision medicine can potentially overcome this issue, as it is founded on extensive knowledge of the druggable genome/proteome. Hence, this review summarizes significant trends and ...
Source: Clinical and molecular hepatology - September 13, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients.
Conclusions: The HCC recurrence rate following 5 recurrence-free years after HCC treatment was high, indicating that HCC patients warrant continued HCC surveillance, even after 5 recurrence-free years. PMID: 32911589 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - September 13, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

From intestinal dysbiosis to alcohol-associated liver disease.
Authors: Mendes BG, Schnabl B Abstract Alcohol-associated intestinal dysbiosis and bacterial overgrowth can lead to a dysregulation of tryptophan metabolism and lower production of indoles. Several of these indole derivatives are aryl hydrocarbon receptor ligands that, in turn, are involved in antimicrobial defense via induction of interleukin-22 (IL-22). IL-22 increases the expression of intestinal regenerating islet-derived 3 (Reg3) lectins, which maintain low bacterial colonization of the inner mucus layer and reduce bacterial translocation to the liver. Chronic alcohol consumption is associated with reduced int...
Source: Clinical and molecular hepatology - September 13, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment.
This study aimed to study the treatment and side effects of GLE/PIB in these patients infected with non-1 genotype (GT) HCV. Methods: We prospectively recruited patients with Child's A cirrhosis and eGFR
Source: Clinical and molecular hepatology - August 30, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop.
Authors: Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW Abstract Clinical practice guidelines are important for guiding the management of specific diseases by medical practitioners, trainees, and nurses. In some cases, the guidelines are utilized as a reference for health policymakers in controlling diseases with a large public impact. With this in mind, practice guidelines for the management of chronic hepatitis B (CHB) have been developed in the United States, Europe, and Asian-Pacific regions to suggest the best-fit recommendations for each social and medical circumstance. Rec...
Source: Clinical and molecular hepatology - August 30, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcino- ma through the Snail/GSK-3/beta-catenin pathway.
Conclusions: The inhibition of PI3K/Akt signaling decreases Snail expression by enhancing the nuclear translocation of GSK-3β, which suppresses EMT in HCC cells, suggesting the potential clinical application of PI3K inhibitors for HCC treatment. PMID: 32829570 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - August 25, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease.
Authors: Kim KS, Lee BW Abstract Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder and is associated with various metabolic diseases, including type 2 diabetes mellitus. There are no approved drugs for NAFLD, and the only approved treatment option is weight reduction. As insulin resistance plays an important role in the development of NAFLD, many anti-diabetic drugs have been evaluated for the treatment of NAFLD. Improvement of liver enzymes has been demonstrated by many anti-diabetic drugs, but histological assessment still remains insufficient. Pioglitazone could become the first-line the...
Source: Clinical and molecular hepatology - August 15, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH.
Authors: Hydes TJ, Ravi S, Loomba R, E Gray M Abstract Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide and affects approximately one third of adults in the United States. The disease is becoming a global epidemic as a result of the rising rates of obesity and metabolic disease. Emerging data suggest weight loss of ≥10% overall body weight is beneficial in resolving steatosis and reversing fibrosis. Prospective trials comparing various diets are limited by lack of sufficient power as well as pre- and post-treatment histopathology, and therefore no specific diet...
Source: Clinical and molecular hepatology - July 19, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Liver graft from donation after circulatory death donor: Real practice to improve graft viability.
Authors: Hashimoto K Abstract Donation after circulatory death (DCD) is an increasing source of liver grafts for transplantation, yet outcomes have been inferior compared to donation after brain death liver transplantation. These worse outcomes are mainly due to the severe graft injury resulting from mandatory warm ischemia during DCD organ recovery. New evidence, however, indicates that improved donor selection and surgical techniques can decrease the risk of graft failure and ischemic cholangiopathy (IC). Under current best practices, DCD organs are retrieved with the super-rapid technique, optimizing timing and ...
Source: Clinical and molecular hepatology - July 12, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Stereotactic body radiation therapy for small ( ≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial.
Conclusions: SBRT showed excellent results as an ablative treatment for patients with small HCCs while showing minimal toxicities. SBRT can be a good alternative for both curative and salvage intents in patients with HCCs that are unsuitable for curative treatments. PMID: 32646200 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - July 12, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma.
Conclusions: The serum levels of myostatin, follistatin, and IL-6 and their correlation with sarcopenia and survival were presented in HCC patients for the first time. The role of the serum follistatin level as a poor prognostic biomarker warrants further study. PMID: 32646201 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - July 12, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Is liver biopsy still useful in the era of non-invasive tests?
Authors: Lim TS, Kim JK PMID: 32646204 [PubMed - in process] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - July 12, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma.
Authors: Han S, Kim DY PMID: 32646205 [PubMed - in process] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - July 12, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
Authors: Jang BK PMID: 32646206 [PubMed - in process] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - July 12, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Fecal microbiota transplantation in alcohol related liver diseases.
Authors: Shasthry SM Abstract The current standard of care for severe alcoholic hepatitis (SAH) has several limitations in that only up to one-third of patients are eligible for steroid therapy. Additionally, steroids have their own issues: a portion of patients do not respond, while there is doubtful long-term benefit in those who do and a large proportion are ineligible to receive steroids entirely and hence have no definitive options for treatment. As such, there is a large gap between the problem and the available solutions. Alcohol causes dysbiosis and also disrupts gut barrier function, consequently promoting...
Source: Clinical and molecular hepatology - June 25, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Macro-aspartate aminotransferase in a healthy woman.
Authors: Lorubbio M, Ognibene A, Salvadori B, Fanelli A, Laffi G PMID: 32570300 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - June 25, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change?
Authors: Kim JH, Sinn DH PMID: 32570301 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - June 25, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Management of liver diseases during the pandemic of coronavirus disease-19.
Authors: Cho JY, Kim SS, Lee YS, Song DS, Lee JH, Kim JH, Korean Association for the Study of the Liver PMID: 32570302 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - June 25, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Novel biomarkers for the management of chronic hepatitis B.
Authors: Inoue T, Tanaka Y Abstract Hepatitis B virus (HBV) cannot be eliminated completely from infected hepatocytes because of the presence of intrahepatic covalently closed circular DNA (cccDNA). As chronic hepatitis B (CHB) can progress to cirrhosis and hepatocellular carcinoma (HCC), it is important to manage CHB to prevent HCC development in high-risk patients with high viral replicative activity or advanced fibrosis. Serum biomarkers are noninvasive and valuable for the management of CHB. Hepatitis B core-related antigen (HBcrAg) correlates with serum HBV DNA and intrahepatic cccDNA. In CHB patients with und...
Source: Clinical and molecular hepatology - June 18, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?
Authors: Kim SY PMID: 32536046 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - June 18, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

How does low-level viremia affect the prognosis of patients with chronic hepatitis B?
Authors: Lee HW, Kim BK PMID: 32521991 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - June 12, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
This study aimed to compare the diagnostic performances of Liver Imaging Reporting and Data System (LI-RADS) 2018 and Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) 2018 criteria on magnetic resonance imaging (MRI) for the noninvasive diagnosis of hepatocellular carcinoma (HCC) in high-risk patients. Methods: This retrospective study included 273 treatment-naïve patients (71 patients with extracellular contrast agent [ECA]-MRI and 202 patients with hepatobiliary agent [HBA]-MRI; 352 lesions including 263 HCCs) with high risk of HCC who underwent contrast-enhanced MRI between 2016 and 2017. Two r...
Source: Clinical and molecular hepatology - June 5, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis.
Authors: Thuy LTT, Hai H, Kawada N Abstract Cytoglobin (Cygb), a stellate cell-specific globin, has recently drawn attention due to its association with liver fibrosis. In the livers of both humans and rodents, Cygb is expressed only in stellate cells and can be utilized as a marker to distinguish stellate cells from hepatic fibroblast-derived myofibroblasts. Loss of Cygb accelerates liver fibrosis and cancer development in mouse models of chronic liver injury including diethylnitrosamine-induced hepatocellular carcinoma, bile duct ligation-induced cholestasis, thioacetamide-induced hepatic fibrosis, and choline-de...
Source: Clinical and molecular hepatology - June 5, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.
Conclusions: After sorafenib failure, the use of nivolumab may be associated with improved OS and better objective response rate as compared to using regorafenib. PMID: 32460459 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - May 30, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
Authors: Woo HY, Park JY, Bae SH, Kim CW, Jang JY, Tak WY, Kim DJ, Kim IH, Heo J, Ahn SH Abstract Background/Aims: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM/LdT+ADV. Methods: This prospective randomized controlled trial examined 91 patients whose serum HBV DNA levels were greater than 60 IU/mL after at least 24 weeks of treatment with LAM/LdT+ADV for LAM-resistant HBV. Patients were randomiz...
Source: Clinical and molecular hepatology - May 30, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir.
This study aimed to evaluate the effects of LLV on HCC development, mortality, and cirrhotic complications among patients according to their adherence to entecavir (ETV) treatment. Methods: We performed a retrospective observational analysis of data from 894 consecutive adult patients with treatment-naïve CHB undergoing ETV treatment. LLV was defined according to either persistent or intermittent episodes of
Source: Clinical and molecular hepatology - May 30, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years.
Conclusions: LB is widely used in clinical practice as an irreplaceable diagnostic tool, even in the era of noninvasiveness. Ultrasonography-guided LB can be performed safely in patients with liver cirrhosis. PMID: 32447878 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - May 27, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Should physicians go out of the way to differentiate between acute hepatitis B and acute exacerbation of chronic hepatitis B?
Authors: Lee HW PMID: 32272816 [PubMed - in process] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - April 12, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

The dilemma of differentiating between acute hepatitis B and chronic hepatitis B with acute exacerbation: Is quantitative serology the answer?
This study aimed to identify laboratory markers for differentiating between the two groups, and to establish the cut-off value for significant markers. . METHODS: A retrospective analysis of records was conducted for patients who presented with clinical features of acute hepatitis along with hepatitis B surface antigen (HBsAg) and IgM antibody to hepatitis B core antigen (IgM anti-HBc) positivity from May 2015 to May 2017. A total of 172 patients were enrolled and grouped as AHB (n=89) and CHB-AE (n=83) based on their history of hepatitis B virus infection and duration of HBsAg persistence. Virological and biochemical ...
Source: Clinical and molecular hepatology - April 12, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

A challenge in distinguishing between acute hepatitis B and acute exacerbation of chronic hepatitis B.
Authors: Baek YH PMID: 32272818 [PubMed - in process] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - April 12, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis?
Authors: Eun HS PMID: 32272819 [PubMed - in process] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - April 12, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Unmet needs of chronic hepatitis C in the era of directacting antiviral therapy.
Authors: Huang CF, Yu ML Abstract The treatment of chronic hepatitis C (CHC) has been revolutionized in an era of all-oral direct-acting antivirals (DAAs) since 2014. Satisfactory treatment efficacy and tolerability can be provided by novel DAAs. Nevertheless, there are still some unmet needs and emerging issues in the treatment of CHC in the DAA era. Certain hard-to-cure populations are prone to have inferior treatment responses, including patients with severe liver decompensation, active hepatocellular carcinoma (HCC), and hepatitis C virus (HCV) genotype 3 (HCV-3) infection and those who experience multiple DAA ...
Source: Clinical and molecular hepatology - March 21, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?
Authors: Jeong SW PMID: 32192273 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 21, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Limited expression of toll-like receptor 9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease.
Authors: Yu JH PMID: 32192316 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 21, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Intricate interpretation of etiology-specific outcome comparison in patients with hepatocellular carcinoma.
Authors: Kim HY, Dufour JF PMID: 32178487 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 18, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?
Authors: Shim JH PMID: 32160729 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 14, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Regulated differentiation of stem cells into an artificial 3D liver as a transplantable source.
Authors: Chen F, Wang H, Xiao J Abstract End-stage liver disease is one of the leading causes of death around the world. Since insufficient sources of transplantable liver and possible immune rejection severely hinder the wide application of conventional liver transplantation therapy, artificial three-dimensional (3D) liver culture and assembly from stem cells have become a new hope for patients with end-stage liver diseases, such as cirrhosis and liver cancer. However, the induced differentiation of single-layer or 3D-structured hepatocytes from stem cells cannot physiologically support essential liver functions d...
Source: Clinical and molecular hepatology - February 28, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Switching to systemic therapy after locoregional treatment failure: Definition and best timing.
Authors: Ogasawara S, Ooka Y, Koroki K, Maruta S, Kanzaki H, Kanayama K, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Kato N Abstract In patients with unresectable hepatocellular carcinoma (HCC) without both macrovascular invasion and extrahepatic metastasis, the initial treatment choice recommended is transarterial chemoembolization (TACE). Before sorafenib came into wide use, TACE had been pointlessly carried out repeatedly. It was in the early 2010s that the concept of TACE refractory was advocated. Two retrospective studies from Japan ...
Source: Clinical and molecular hepatology - January 17, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.
Authors: Korean Association for the Study of the Liver (KASL) PMID: 31918536 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 11, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
Authors: Kumar R, Goh BG, Kam JW, Chang PE, Tan CK Abstract Background and Aim: Non-alcoholic liver disease and alcoholic liver disease begin as simple steatosis that may progress to steatohepatitis and ensuing liver-related complications such as cirrhosis and hepatocellular carcinoma (HCC). We explored differences in characteristics between non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis-related (ASH) HCC. Methods: NASH and ASH patients were identified from our department's prospective HCC database. A total of 54 and 45 patients met predefined inclusion and exclusion criteria for the NASH-HC...
Source: Clinical and molecular hepatology - January 10, 2020 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

A leap for the journal: Clinical and Molecular Hepatology enters a new era.
Authors: Kim YJ PMID: 31838835 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - December 18, 2019 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Drug induced liver injury: East versus West - a systematic review and meta-analysis.
Authors: Low EXS, Zheng Q, Chan E, Lim SG Abstract Drug induced liver injury (DILI) may be different in the East compared to the West due to differing disease prevalence, prescribing patterns and pharmacogenetic profiles. To review existing literature on causative agents of DILI in the East compared to the West, a comprehensive literature search was performed on electronic databases: MEDLINE/PubMed, Embase, Cochrane Library and China National Knowledge Infrastructure without language restrictions. Studies which involve patients having DILI and reported the frequency of causative agents were included. A random effec...
Source: Clinical and molecular hepatology - December 11, 2019 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Limited expression of TLR9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease.
Conclusions: The positive associations between TLR9 and anthropometric, clinical, and histological features and the crucial role of IFN-γ-in NAFLD suggest that limited TLR9 expression and production of IFN-γ play a protective role in patients with simple steatosis. PMID: 31795627 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - December 7, 2019 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with my- eloproliferative neoplasms.
Authors: Lee J, Sung PS, Eom KS, Yang H, Lee SK, Bwa AH, Lozada A, Jang JW, Bae SH, Choi JY, Yoon SK PMID: 31760741 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - November 27, 2019 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Multimodal sequential treatment for occluded TIPS: case report and review of literature.
Authors: De Matthaeis N, Di Stasi C, Pizzolante F, Manfredi R, Rapaccini GL, Miele L PMID: 31735021 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - November 20, 2019 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard.
We examined US sensitivity for diagnosis of HCC in obese patients. Methods: Liver transplant patients data with HCC in explant was used (January 2012-December 2017). All patients underwent liver US within 3 months of diagnosis of HCC. Number/size of HCC lesions were extracted from radiologic and pathologic reports. Obesity was defined as BMI ≥30 kg/m2. Results: One hundred sixteen patients were included. 80% were male, with mean BMI of 31 kg/m2. The most common underlying liver disease was hepatitis C virus (62%). At the time of diagnosis, median number of HCC lesions was 2 (interquartile range [IQR], 1-3), and ...
Source: Clinical and molecular hepatology - November 17, 2019 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research

Application of transient elastography in nonalcoholic fatty liver disease.
This article reviews the performance and limitations of transient elastography in NAFLD and highlights its clinical applications. We also discuss the reliability criteria for transient elastography examination and factors associated with false-positive liver stiffness measurements. PMID: 31696690 [PubMed - as supplied by publisher] (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - November 8, 2019 Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research